Disease · MONDO_0006451
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 vs No Treatment: Weeks 5-6, Group 1; Week 3, Group 2: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | 41 of 41 | 15 of 15 | 56 | NCT01621568 | Trial comparisons |
| Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 vs No Treatment: Weeks 5-6, Group 1; Week 3, Group 2: deaths from any cause | 38 of 41 | 15 of 15 | 56 | NCT01621568 | Trial comparisons |
| Treatment: Weeks 1-4, Group 1; Weeks 1-2, Group 2 vs No Treatment: Weeks 5-6, Group 1; Week 3, Group 2: serious adverse events | 38 of 41 | 15 of 15 | 56 | NCT01621568 | Trial comparisons |
| Thymoma vs Thymic Carcinoma: serious adverse events | 13 of 24 | 14 of 21 | 45 | NCT00010257 | Trial comparisons |
| Thymoma Patients vs Thymic Patients: Number of Participants With a Partial Response | 2 of 25 | 0 of 16 | 41 | NCT00589290 | Trial comparisons |
| Thymoma vs Thymic Carcinoma: Grade 3/4 Treatment Related Adverse Events | 1 of 16 | 1 of 11 | 27 | NCT00198133 | Trial comparisons |
| Thymoma vs Thymic Carcinoma: serious adverse events | 2 of 16 | 3 of 11 | 27 | NCT00198133 | Trial comparisons |
| Thymoma vs Thymic Carcinoma: Expected Toxicities Including Skin Rashes and Diarrhea | 10 of 12 | 3 of 9 | 21 | NCT00718809 | Trial comparisons |
| Thymoma vs Thymic Carcinoma: serious adverse events | 2 of 12 | 1 of 9 | 21 | NCT00718809 | Trial comparisons |
| Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) vs Active Comparator: Arm B (Carboplatin, Paclitaxel): deaths from any cause | 1 of 8 | 2 of 9 | 17 | NCT03694002 | Trial comparisons |
| Experimental: Arm A (Ramucirumab, Carboplatin, Paclitaxel) vs Active Comparator: Arm B (Carboplatin, Paclitaxel): serious adverse events | 3 of 8 | 0 of 9 | 17 | NCT03694002 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006451/comparisons